NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

市場焦點:被套細胞淋巴瘤 (MCL)

Market Spotlight: Mantle Cell Lymphoma

出版商 Datamonitor Healthcare 商品編碼 973486
出版日期 內容資訊 英文 41 Pages
商品交期: 最快1-2個工作天內
價格
市場焦點:被套細胞淋巴瘤 (MCL) Market Spotlight: Mantle Cell Lymphoma
出版日期: 2020年10月15日內容資訊: 英文 41 Pages
簡介

2017年,全球被套細胞淋巴瘤(MCL)病例約14030例,預計到2026年將增至18010例。

本報告提供被套細胞淋巴瘤 (MCL) 調查分析,提供主要的上市藥·開發平台藥物,臨床試驗,最近的事件和分析師的見解,今後的法規趨勢,成功的可能性,專利資訊,10年預測等相關的系統性資訊。

目錄

內容

概要

要點

疾病的背景

  • 疾病定義
  • 患者市場區隔
  • 症狀
  • 危險因素
  • 診斷

治療

  • 標靶治療
  • 化療
  • 類固醇
  • 免疫調節藥
  • 放射線治療
  • 蛋白酶體抑制劑
  • 幹細胞移植

流行病學

上市藥

開發平台藥物

最近的事件和分析師的見解

今後主要的事件

主要的法規趨勢

成功的可能性

授權與資產取得交易

  • 醫療產業形成的交易

商機

臨床試驗形勢

  • 贊助商:各狀態
  • 贊助商:不同階段
  • 最近的事件

參考文獻

  • 處方資訊

附錄

目錄
Product Code: DMKC0203935

This Market Spotlight report covers the Mantle Cell Lymphoma (MCL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2017, there were approximately 14,030 incident cases of mantle cell lymphoma (MCL) worldwide, and forecasts that number to increase to 18,010 incident cases by 2026.

It is estimated that the majority of diagnosed cases were male in 2017.

The incidence of MCL is highest among older individuals aged 60+ years. Approved drugs in the MCL space focus on a wide variety of targets. The majority of these drugs are administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.

The majority of industry-sponsored drugs in active clinical development for MCL are in Phase II. Therapies in active clinical development for MCL focus on a wide variety of targets. These drugs are administered via the oral and intravenous routes.

High-impact upcoming events for drugs in the MCL space comprise topline Phase II trial results for parsaclisib; topline Phase II/III trial results for TG-1303 and umbralisib; topline Phase III trial results for Venclexta, Imbruvica, and Calquence; and an expected CHMP opinion for Tecartus.

The overall likelihood of approval of a Phase I hematologic asset is 9.4%, and the average probability a drug advances from Phase III is 60.3%. Drugs, on average, take 9.2 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for MCL have been in the early and mid-phases of development, with 90% of trials in Phase I-II, and only 10% in Phase III-IV.

The US has a substantial lead in the number of MCL clinical trials globally. France and Germany lead the major European markets, while China has the top spot in Asia.

Johnson & Johnson has the highest number of completed clinical trials for MCL, with 15 trials. Johnson & Johnson leads industry sponsors with the highest overall number of clinical trials for MCL, followed by Bristol Myers Squibb.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Disease definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Targeted therapies
  • Chemotherapies
  • Steroids
  • Immunomodulators
  • Radiation therapy
  • Proteasome inhibitors
  • Stem cell transplantation

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Tecartus for MCL (December 9, 2019)
  • Copiktra for MCL (July 25, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Gilead/Kite Gain Second CAR-T Approval With Tecartus, Price On Par With Their First
  • Brukinsa Sprints To Accelerated Approval For MCL

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Deals Shaping The Medical Industry, January 2020

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Global trends in incident cases of MCL, 2017-26
  • Figure 2: Global incident cases of MCL, by age, 2017
  • Figure 3: Overview of pipeline drugs for MCL in the US
  • Figure 4: Pipeline drugs for MCL, by company
  • Figure 5: Pipeline drugs for MCL, by drug type
  • Figure 6: Pipeline drugs for MCL, by classification
  • Figure 7: Tecartus for MCL (December 9, 2019): Phase II - ZUMA-2 (r/r MCL)
  • Figure 8: Key upcoming events in MCL
  • Figure 9: Probability of success in the MCL pipeline
  • Figure 10: Clinical trials in MCL
  • Figure 11: Top 10 drugs for clinical trials in MCL
  • Figure 12: Top 10 companies for clinical trials in MCL
  • Figure 13: Trial locations in MCL
  • Figure 14: MCL trials status
  • Figure 15: MCL trials sponsors, by phase

LIST OF TABLES

  • Table 1: Global incident cases of MCL, 2017-26
  • Table 2: Global incident cases of MCL, by gender, 2017
  • Table 3: Marketed drugs for MCL
  • Table 4: Pipeline drugs for MCL in the US
  • Table 5: Tecartus for MCL (December 9, 2019)
  • Table 6: Copiktra for MCL (July 25, 2019)
  • Table 7: Historical global sales, by drug ($m), 2015-19
  • Table 8: Forecasted global sales, by drug ($m), 2020-24